Recent scientific research has reportedly highlighted the beneficial impact of Bioiberica’s Mobilee, a hyaluronic acid (HA) matrix ingredient, on joint health. The company says this study adds to a growing bank of evidence demonstrating the ingredient’s bioavailability and its ability to increase the production of HA in the joints.
The randomised, double-blind clinical study set out to evaluate the effects of the ingredient on synovial fluid concentrations of several selected biomarkers in 55 dogs. During the study a control group was given a placebo, whereas a second group received supplementation for 10 weeks following surgery. Synovial fluid samples were obtained before surgery and at 10 weeks postoperatively to measure key biomarkers of osteoarthritis, including HA, haptoglobin, nitric oxide and paraoxonase-1 (PON-1).
The study found the ingredient significantly improved biomarkers of osteoarthritis in the group that received the supplement. After 10 weeks, there was a significant increase in HA concentration in the synovial fluid and a decrease in PON-1 concentrations compared to baseline. The positive changes in biomarkers, as a result of post-op oral supplementation, may represent a potential treatment for the management of joint conditions.
“Despite this research involving dogs specifically, the results are an important indicator for Mobilee’s effect in humans too. The findings further contribute to a robust body of evidence which indicates Mobilee’s ability to increase endogenous HA levels and its role in supporting joint and muscle health,” said Jaume Reguant, Healthcare Director, Bioiberica. “Science is at the heart of everything we do at Bioiberica – it’s the means through which we continue to deliver cutting-edge ingredients to support our customers’ product developments.”
